Due to the special nature of medicines, returns and exchanges are not supported.
Final delivery from the nearest overseas warehous NEW

Fluticasone Propionate Inhaled Aerosol.

Functional Indications:
There may be differences in the usage and dosage of different dosage forms and specifications of this product. Please read the specific drug instructions for use, or follow your doctor’s advice. Fluticasone Propionate Nasal Spray (Fluticasone Propionate Nasal Spray): For the prevention and treatment of seasonal allergic rhinitis (including hay fever) and perennial allergic rhinitis. Fluticasone propionate inhalation aerosol: suitable for the preventive treatment of asthma in adults and children over 1 year old (including 1 year old). 1. Adults: (1) Mild asthma: On the basis of regular daily treatment, patients need to be given intermittent bronchodilator drugs to relieve asthma symptoms. (2) Moderate asthma: patients who are receiving preventive treatment or bronchodilator treatment alone, but whose asthma is still unstable or continues to worsen. (3) Severe asthma: patients with severe chronic asthma who rely on systemic administration of corticosteroids to fully control their symptoms. Once inhaled fluticasone propionate is initiated, the need for oral corticosteroids can be significantly reduced or eliminated in many patients. 2. Children: Any child who needs preventive drug treatment, including patients whose symptoms cannot be controlled by current preventive treatment. Fluticasone propionate aerosol inhalation suspension: 1. Treatment of mild to moderate acute asthma exacerbations in children and adolescents aged 4-16 years. 2. Fluticasone propionate has significant anti-inflammatory effects in the lungs. 3. In patients with asthma who have previously received only bronchodilator therapy or other preventive treatments, fluticasone propionate can reduce asthma symptoms and acute exacerbations. 4. The symptoms of relatively short-lived acute attacks can generally be relieved by using fast-acting bronchodilators, but longer-lasting acute attacks require treatment with glucocorticoids as soon as possible to control inflammation. Fluticasone Propionate Cream: 1. Adults: It is suitable for inflammatory and itchy skin diseases that can be relieved by various corticosteroids, such as eczema including specific eczema and discoid eczema; nodular prurigo; psoriasis (generalized plaques) (except lumpy type); neurodermatoses include lichen simplex; lichen planus; seborrheic dermatitis; contact allergy; discoid lupus erythematosus; adjunct to systemic steroid therapy for generalized erythema, insect bite dermatitis; milia. 2. Children: Children over 1 year old (including 1 year old) who are ineffective with low-potency corticosteroids can use this product to relieve inflammation and itching caused by atopic dermatitis under the guidance of a doctor. Children with other skin conditions that may be relieved by corticosteroids should consult their physician before using this product.
This product comes in a variety of dosage forms and specifications. The same medicine produced by different manufacturers may have inconsistent instructions. Please read the drug instructions carefully before taking the medicine and follow the doctor’s instructions. Fluticasone Propionate Nasal Spray (Fluticasone Propionate Nasal Spray): 1. Spray into the nasal cavity: Spray the right nostril with your left hand and the left nostril with your right hand. Avoid spraying directly into the nasal septum. 2. Adults and children over 12 years old: 2 sprays into each nostril, once a day (200 g daily), preferably in the morning. Some patients may need 2 sprays in each nostril, twice daily, once in the morning and once in the evening until symptoms improve. When symptoms are controlled, the maintenance dose is 1 spray in each nostril, once daily. The maximum daily dose is no more than 4 sprays in each nostril. 3. Instructions for use and operation: Before use: (1) Shake the bottle gently, hold the edge of the cap with your index finger and thumb, and remove the cap. (2) Hold the sprayer with your index and middle fingers on one side of the nozzle and your thumb on the bottom of the bottle. (3) If it is used for the first time or has not been used for a week or more, please check whether the sprayer spray is normal. You can move the nozzle away from your body and press down several times until the sprayer sprays normally. When using: (4) Breathe gently through the nose. (5) Press one nostril, put the nozzle into the other nostril, and tilt your head slightly forward. Keep the bottle upright. (6) Start inhaling through your nose. At this time, press the bottle with your finger to make it spray out 1 spray. (7) Exhale through your mouth. If you need to spray again, repeat steps 6 and 7. (8) Repeat steps 5, 6 and 7 for the other nostril. After use: (9) Dry with gauze or handkerchief, cap the bottle, and clean the device thoroughly as follows every 4 days. 4. Cleaning: (1) Gently pull off the bottle cap and clean with hot water. (2) Shake the bottle, pour out the remaining water, and dry in a warm place to avoid overheating. (3) Carefully put the nozzle back on the bottle and close the bottle cap. (4) If the nozzle is clogged, remove it as in step 1 above and soak it in warm water. Rinse with cold water, dry, and place back on the bottle. Do not use a pin or other sharp object to try to get the nozzle open. Fluticasone propionate inhalation aerosol: 1. This product can only be inhaled through the mouth. Patients who have difficulty in inhaling and inhaling simultaneously can use an aerosol storage tank. 2. Patients should pay attention to the inhalation aerosol of this drug for preventive treatment, and should use it regularly even if they are asymptomatic. Effective within 4-7 days after administration. 3. If the patient finds that the relief from rapid-acting bronchodilator therapy begins to wear off or requires a larger dose than usual, he or she must seek medical help. 4. Adults and children over 16 years old take 100-1000 g each time, 2 times a day. Usually 2 puffs each time, 2 times a day. 5. When the dosage exceeds 1000μg (500μg, twice a day), a spray tank should be used to reduce side effects on the mouth and throat. 6. The patient should be given an appropriate initial dose based on the severity of the condition. Prescribers should be aware that fluticasone propionate may require lower doses for disease control than some other inhaled corticosteroids. The usual initial dose is: (1) Mild asthma: 100-250 g each time, 2 times a day. (2) Moderate asthma: 250-500&m;g each time, 2 times a day. (3) Severe asthma: 500-1000&m;g each time, 2 times a day. (4) Children over 1 year old: 50-100&m;g each time, 2 times a day. It is recommended that children under 8 years old use a spray tank for administration. The starting dose should be based on the severity of the condition. Clinical trials in children aged 1 to 4 years have shown that optimal control of asthma symptoms is achieved with a dose of 100 µg twice daily administered via a mask-worn spacer. 7. For special patients, there is no need to adjust the dosage for elderly patients or patients with liver or kidney damage. The dose should be gradually reduced to the lowest dose that effectively controls asthma. Fluticasone propionate aerosol inhalation suspension: 1. Treatment of acute asthma attacks in children and adolescents aged 4 to 16 years: 1 mg twice daily. (1) The initial dose of aerosolized fluticasone propionate should be given to children based on the severity of their disease. The dose is then adjusted based on individual response until the condition is controlled or reduced to the minimum effective dose. (2) When treating an acute asthma attack, it is recommended to use the highest dose in this range, up to 7 days after the attack. A dose reduction should then be considered. (3) Please inhale fluticasone propionate aerosol inhalation suspension through the aerosol generated by the nebulizer under the guidance of a doctor. Since the dosing process may be affected by many factors, the instructions for use provided by the nebulizer manufacturer should be consulted. It is recommended to use mouthpiece aerosol inhalation of fluticasone propionate aerosol inhalation suspension. If a mask is used to administer the drug, nasal inhalation may occur. (4) In a phase III clinical study in China, the German Berry LCSPRINT Junior nebulizer was used in combination with the Berry BOYSX compressor to administer the drug, which confirmed the safety and effectiveness of this product. The clinical effectiveness and safety of this product have not been verified using other nebulizer models. (5) It is not recommended to use an ultrasonic nebulizer to inhale fluticasone propionate nebulized inhalation suspension. (6) Fluticasone propionate aerosol inhalation suspension shall not be used for injection. (7) If you find that the symptom-relieving effect of short-acting bronchodilators is reduced or you need to inhale a larger dose than before, you must seek medical treatment in time to ensure Fluticasone acid aerosol inhalation suspension is used for better inhalation or to extend the time of drug inhalation. It can be diluted with sodium chloride injection immediately before administration. (8) Since many nebulizers deliver medication by continuous air flow, aerosolized drugs are likely to be released into the surrounding environment. Fluticasone propionate nebulizer inhalation suspension nebulization therapy should therefore be given in a well-ventilated room, especially if several patients in the hospital are using nebulizers at the same time. (9) Maintenance treatment after an acute attack can use pressure metered inhalation aerosol or dry powder inhalation. 2. Special patient populations: No dose adjustment is required in patients with renal or hepatic impairment. Fluticasone propionate cream: 1. Eczema/dermatitis: For adults and children over one year old (including one year old), apply a thin layer of cream to the affected area once a day. 2. Other indications: Apply a thin layer of cream to the affected area twice daily. 3. Duration of use: This product should be used every day until the disease symptoms are controlled. The frequency of medication should be controlled at the lowest effective dose. When using this product in children, if symptoms do not improve after 7-14 days of treatment, the drug should be discontinued and re-evaluated. If symptoms are controlled (usually within 7-14 days), the frequency of medication needs to be reduced to the minimum effective dose and the shortest duration. It is recommended to use this product continuously for no longer than 4 weeks. This product is for topical use.
Adverse reactions:
There may be differences in the usage and dosage of different dosage forms and specifications of this product. Please read the specific drug instructions for use, or follow your doctor’s advice. Fluticasone Propionate Nasal Spray (Fluticasone Propionate Nasal Spray): 1. Very common: epistaxis. 2. Common: Like other nasal inhalants, it has an unpleasant taste and smell after use, causing headaches and can cause dryness and irritation in the nose and throat. 3. Very rare: allergic/anaphylactoid reactions, bronchospasm, rash, facial or tongue edema, nasal septum perforation, glaucoma, elevated intraocular pressure and cataracts, etc. Fluticasone propionate inhalation aerosol: Adverse events are listed separately according to different systems, organs and incidence rates. Incidence is defined as: very common (≥1/10), common (≥1/100 and <1/10), uncommon (≥1/1000 and <1/100), rare≥1 /10000 and <1/1000), very rare (<1/10000) including case reports. Very common, common, and uncommon are usually determined from clinical trial data. Rare and very rare adverse events are usually spontaneous data. 1. Infections and invasive diseases: Very common: Candidiasis of the mouth and throat (thrush). Rare: Esophageal candidiasis. 2. Immune system disorders: Uncommon: skin allergic reactions. Very rare: angio(neuro)edema (mainly facial and oropharyngeal edema), respiratory syndrome (dyspnea and/or bronchospasm) and anaphylactoid reactions. 3. Endocrine disorders: Very rare: Cushing’s syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, reduced bone mineral density, cataracts and glaucoma. 4. Metabolic and nutritional disorders: Very rare: hyperglycemia. 5. Mental disorders: Very rare: anxiety, sleep disturbance, behavioral changes including hyperactivity and irritability (mainly seen in children). 6. Respiratory system, chest and mediastinum: Common: Hoarseness. Very rare: Abnormal bronchospasm. 7. Skin and subcutaneous tissue disorders: common: contusion. 8. Gastrointestinal system diseases: Very rare: indigestion. 9. Musculoskeletal and connective tissue diseases: Very rare: joint pain. 10. Adverse reactions seen in studies in children aged 1-4 years: In two studies in children aged 1-4 years, fluticasone propionate 50 gbid., 100 gbid. and 250 gbid. was administered compared with placebo. Treatment was also well tolerated. In these studies, reported incident rates of rash, allergic skin reaction, throat irritation, nasal irritation, epistaxis, hoarseness/dysphonia, and oral/throat Candida infection ranged between 0% and 5%. The incidence of these events did not differ significantly between treatment groups. Fluticasone propionate aerosol inhalation suspension: 1. Infection (1) is very common: oropharyngeal candidiasis. Some patients may develop candida infection in the oropharynx (thrush) after use. For these patients, they can prevent the occurrence of candida infection in the oropharynx by gargling after taking the medication. For symptomatic candidiasis, topical antibiotics can be used. fungal drug treatment, while still continuing to use fluticasone propionate. (2) Rare: esophageal candidiasis. 2. Immune system disorders report the following hypersensitivity reactions: (1) Uncommon: skin hypersensitivity reactions. (2) Rare: angioedema (mainly facial and oropharyngeal edema), respiratory symptoms (dyspnea and/or bronchospasm). (3) Very rare: allergic reaction. 3. Common skin and subcutaneous tissue diseases: contusion. 4. Possible systemic effects of endocrine disorders include (see Precautions). Rare: Adrenal suppression, growth retardation in children and adolescents, reduced bone mineral density, cataracts, glaucoma. Cushing’s syndrome and Cushingoid features. 5. Psychiatric disorders are very rare: anxiety, sleep disturbance, and behavioral changes including hyperactivity and irritability (mainly in children). 6. Metabolic and nutritional disorders are very rare: hyperglycemia. 7. Respiratory, chest and mediastinal diseases (1) Common: Hoarseness. Hoarseness may occur after inhalation of fluticasone propionate, which can be prevented by gargling with water immediately after inhalation. (2) Rare: Paradoxical bronchospasm (see Precautions). Fluticasone propionate cream: 1. In placebo-controlled clinical trials, the most common side effects were skin infection, infectious eczema, viral warts, herpes simplex, impetigo, atopic dermatitis, eczema, exacerbation of eczema, erythema, Burning, stinging, skin irritation, folliculitis, blisters, numbness of fingers, and dry skin. 2. In open clinical trials in children, common side effects were burning sensation, dark erythema, erythematous rash, facial telangiectasia, non-facial telangiectasia, and urticaria. If allergy occurs, the medication should be discontinued immediately. 2. Adverse reactions such as inflammation, folliculitis, acne-like rash, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, skin atrophy, striae and prickly heat are rare, but their frequency is obvious when encapsulation therapy is used Increase. 4. Long-term and large-scale use of corticosteroids can cause local skin atrophy, manifested as skin thinning, atrophic striae, telangiectasia, hirsutism and hypopigmentation. 5. Long-term application of large amounts or large areas of corticosteroids may lead to hyperadrenocortical function through sufficient systemic absorption. This phenomenon is more likely to occur in infants and young children and patients treated with packet therapy. The use of diapers after medicated infants should also be considered pack therapy. 6. It is rare to induce pustular psoriasis during the use of corticosteroids to treat psoriasis or after discontinuation of treatment. There have been reports of worsening of skin disease symptoms and physical symptoms after taking the drug.
Medication contraindications:
There may be differences in the usage and dosage of different dosage forms and specifications of this product. Please read the specific drug instructions for use, or follow your doctor’s advice. 1. It is prohibited to be used by those who are allergic to any ingredient in this product. 2. It is prohibited to be used for rosacea, acne vulgaris, and rosacea.

Brand: drops Categories:


Featured products

Laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor.